Natural Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Review

Comb Chem High Throughput Screen. 2023;26(15):2668-2678. doi: 10.2174/1386207326666230627122630.

Abstract

PCSK9 (proprotein convertase subtilisin/kexin type 9) is an enzyme that helps to reduce cardiovascular events. This clinical result is attributable primarily to the crucial involvement of PCSK9 in regulating the low-density lipoprotein cholesterol level. Because oral anti-PCSK9 medications have yet to be available, the benefits of this unique treatment approach have been diminished. Identifying naturally occurring PCSK9 inhibitors may lead to considerable progress in this regard. These inhibitors serve as a starting point for producing oral and effective components that could be used with statins to boost the proportion of patients who achieve their LDL-cholesterol goals. In this review, we have briefly summarised the recent information regarding natural components or extracts that have been shown to inhibit PCSK9 activity.

Keywords: ER.; LDL; PCSK9; cholesterol; inhibitors; monoclonal antibodies.

Publication types

  • Review

MeSH terms

  • Cholesterol, LDL
  • Humans
  • PCSK9 Inhibitors*
  • Proprotein Convertase 9*
  • Subtilisins

Substances

  • PCSK9 protein, human
  • Proprotein Convertase 9
  • PCSK9 Inhibitors
  • Cholesterol, LDL
  • Subtilisins